FDA post-market obligations for drugs and biologics
Once a drug or biological product is on the market, the application holder must review all adverse experience information it receives and report qualifying cases on fixed timelines. It must also submit periodic reports on safety and distribution, notify FDA of changes to the approved conditions and keep defined records. For drugs approved under an NDA or ANDA, these duties sit in 21 CFR §§ 314.70, 314.80, 314.81 and 314.98.1 For licensed biological products they sit in 21 CFR §§ 600.12 through 600.15 and §§ 600.80 through 600.82.2
Adverse experience review and 15-day alert reports
Each applicant holding an approved NDA must promptly review all adverse drug experience information obtained or received from any source, foreign or domestic. That includes commercial marketing experience, postmarketing clinical investigations, epidemiological and surveillance studies, reports in the scientific literature and unpublished scientific papers. Any person subject to the reporting requirements must also develop written procedures for the surveillance, receipt, evaluation and reporting of postmarketing adverse drug experiences to FDA.1
The applicant must report each adverse drug experience that is both serious and unexpected as soon as possible and no later than 15 calendar days from initial receipt of the information. This applies to foreign and domestic cases alike. The applicant must promptly investigate the experiences that are the subject of these reports and submit followup reports within 15 calendar days of receipt of new information or as requested by FDA. The 15-day requirements also apply to any person other than the applicant whose name appears on the label of an approved drug product as a manufacturer, packer or distributor.1
A serious adverse drug experience is one that results in death, a life-threatening experience, inpatient hospitalization or prolongation of hospitalization, persistent or significant disability or incapacity, or a congenital anomaly or birth defect. Important medical events that require medical or surgical intervention to prevent one of those outcomes may also be treated as serious. An adverse drug experience is unexpected when the current labeling for the drug product does not list it, including an event of greater severity or greater specificity than the labeled event.1
The same structure governs licensed biological products. Any person holding a biologics license under § 601.20 must promptly review all adverse experience information pertaining to its product, must develop written procedures and must submit 15-day Alert reports on the same 15-calendar-day clock.2 A person named on the label as a manufacturer, packer, distributor, shared manufacturer or joint manufacturer may meet its obligation by submitting each report of a serious adverse experience to the applicant of the final product within 5 calendar days of initial receipt.2
Periodic and annual safety reporting
Biologics applicants submit periodic adverse experience reports covering each adverse experience that was not the subject of a 15-day Alert report. These run at quarterly intervals for 3 years from the date of issuance of the biologics license and then at annual intervals. Each quarterly report is due within 30 days of the close of the quarter and each annual report within 60 days of the anniversary date of issuance of the license. FDA may extend or reestablish quarterly reporting by written notice.2
Each periodic report contains a narrative summary and analysis, an analysis of the 15-day Alert reports submitted during the interval, a history of actions taken since the last report because of adverse experiences and an index of the individual case safety reports submitted. It also contains an ICSR for each serious expected and nonserious adverse experience. Periodic reporting does not extend to adverse experience information from postmarketing studies, the scientific literature or foreign marketing experience, apart from information covered by the 15-day Alert requirement.2
For drugs, § 314.81 sets the annual report. The applicant submits two copies each year within 60 days of the anniversary date of U.S. approval, accompanied by Form FDA 2252. The report contains a summary of significant new information that might affect safety, effectiveness or labeling, together with a description of actions taken or intended in response. It also contains distribution data with National Drug Code numbers and dosage units distributed for domestic and foreign use, authorized generic drug entry and cessation dates where applicable, and currently used labeling with a representative sample of package labels.1
Holders of approved ANDAs carry the same load. Section 314.98 requires compliance with § 314.80 for adverse drug experience reporting and recordkeeping, and with § 314.81 and section 505(k) of the act for other postmarketing reports.1
Field alert reports and biological product deviation reports
An NDA applicant must submit a field alert report to the FDA district office responsible for the facility within 3 working days of receipt of the information. Two categories trigger it. The first is any incident causing the drug product or its labeling to be mistaken for, or applied to, another article. The second is bacteriological contamination, a significant chemical, physical or other change or deterioration in the distributed product, or failure of one or more distributed batches to meet the specification in the application. The information may go by telephone or other rapid means with prompt written followup.1
The parallel channel for licensed biologics is the biological product deviation report on Form FDA 3486. The licensed manufacturer who had control over the product when the deviation occurred must report any event that meets three criteria together. It represents a deviation from current good manufacturing practice, applicable regulations, standards or established specifications that may affect safety, purity or potency, or an unexpected or unforeseeable event with that potential. It occurs in the manufacturer’s facility or a facility under contract. It involves a distributed biological product. The report is due no later than 45 calendar days from the date the manufacturer or its agent acquires information reasonably suggesting a reportable event. Manufacturers of blood and blood components report under § 606.171 instead.2
Changes to an approved application
The applicant must notify FDA about each change in each condition established in an approved NDA beyond the variations already provided for in the application. Depending on the type of change, notification is by a supplement under § 314.70(b) or (c) or by inclusion in the annual report under § 314.70(d). The NDA holder must assess the effects of the change before distributing a drug product made with a manufacturing change.1
Major changes require an approved supplement before distribution of product made using the change. These are changes to any of the following with a substantial potential to have an adverse effect on identity, strength, quality, purity or potency as those factors relate to safety or effectiveness.
- the drug substance
- the drug product
- the production process
- quality controls
- equipment
- facilities
The listed examples include the following.
- formulation and specification changes
- changes affecting sterility assurance
- changes in drug substance synthesis that may affect the impurity profile
- most labeling changes
- container closure system changes
- for biotechnology-derived substances, changes in viral removal methods, source material or cell line
The applicant must promptly revise all promotional labeling and advertising to make it consistent with any implemented labeling change.1
Only the applicant may submit a supplement, and the information in it is limited to what supports the change.1 An ANDA holder follows §§ 314.70 and 314.71, subject to one limit. A supplement may not change the reference listed drug, which requires a new ANDA. A different strength may still be sought by supplement.1 An NDA holder submitting a supplement under § 314.70 must also submit patent information on the required FDA declaration form for patents claiming the drug or an approved method of using it. Process patents, packaging patents, metabolite patents and intermediate patents must not be submitted.1
Ownership of an application may be transferred. The former owner submits a document stating that all rights have been transferred. The new owner submits a signed application form, a commitment to the agreements and conditions in the application, the effective date and either a statement that it holds a complete copy of the approved application or a request for one from FDA.1
Postapproval conditions under accelerated approval and the animal rule
A product approved under § 314.510 on a surrogate endpoint is subject to the requirement that the applicant study the drug further to verify and describe its clinical benefit, and the applicant must carry out those studies with due diligence. FDA may also impose distribution or use restrictions under § 314.520. Postmarketing recordkeeping and safety reporting follow §§ 314.80 and 314.81 as for any approved drug product.1
Promotional materials carry a distinct rule under these subparts. During the preapproval review period the applicant submits copies of all promotional materials intended for dissemination or publication within 120 days following approval. After that 120-day point the applicant submits promotional materials at least 30 days before intended initial dissemination or publication. The same requirement appears at § 314.640 for products approved under the animal rule.1
Approval under § 314.610 based on animal efficacy studies carries three requirements: postmarketing studies to verify and describe clinical benefit when feasible and ethical, restrictions to ensure safe use where needed, and patient labeling explaining that approval rested on animal efficacy studies. FDA notifies the applicant when it determines that these postapproval requirements are no longer necessary.1
Records, samples and supply notifications
Records of each step in the manufacture and distribution of a licensed biological product must be made concurrently with performance. The retention period is no less than 5 years after the records of manufacture have been completed or 6 months after the latest expiration date for the product, whichever is later. Manufacturers also retain a representative sample of each lot for at least 6 months after the expiration date, subject to the exclusions in § 600.13. Distribution reports go to CBER or CDER at 6-month intervals in electronic format, listing bulk and fill lot numbers, expiration dates and release dates.2
Section 600.82 requires written notice to FDA of a permanent discontinuance of manufacture or of an interruption likely to lead to a meaningful disruption in supply. This applies to prescription biological products that are life supporting, life sustaining or intended for use in preventing or treating a debilitating disease or condition. Notice is due at least 6 months before the event. Where 6 months’ notice was not possible because the event was not reasonably anticipated, notice is due as soon as practicable and no later than 5 business days after it occurs. Where an applicant fails to notify, FDA issues a letter, the applicant must respond within 30 calendar days and FDA makes the exchange public within 45 calendar days unless it finds a reasonable basis for the failure.2
Failure to report has consequences at the application level. FDA may propose withdrawal of approval where the applicant has failed to establish a system for maintaining required records, or has repeatedly or deliberately failed to maintain records or make required reports under section 505(k), § 314.80, § 314.81 or § 314.98.1 Approved drugs remain subject to the adulteration and misbranding provisions of sections 501, 502 and 503 of the act.1
Questions people also ask
How quickly must a serious and unexpected adverse event be reported to FDA after approval? The applicant must report each adverse experience that is both serious and unexpected, foreign or domestic, as soon as possible and no later than 15 calendar days from initial receipt of the information. Followup reports are due within 15 calendar days of receipt of new information or when FDA requests them. This deadline applies to drugs under § 314.80 and to licensed biological products under § 600.80.12
Do generic drug applicants have the same postmarketing reporting duties as NDA holders? Yes. Section 314.98 requires each holder of an effective approved ANDA to comply with § 314.80 for adverse drug experience reporting and recordkeeping. The same section requires the reports under § 314.81 and section 505(k) of the act for each approved abbreviated application.1
How often are periodic adverse experience reports due for a licensed biological product? They are due quarterly for 3 years from the date of issuance of the biologics license and annually after that. Quarterly reports are due within 30 days of the close of the quarter and annual reports within 60 days of the anniversary date of issuance of the license. FDA may extend or reestablish quarterly reporting by written notice.2
When does a manufacturing change need FDA approval before the product is distributed? A prior approval supplement is required for any change in the following with a substantial potential to have an adverse effect on identity, strength, quality, purity or potency as these relate to safety or effectiveness.
- the drug substance
- the drug product
- the production process
- quality controls
- equipment
- facilities
Section 314.70(b)(2) lists examples, including sterility assurance changes and most labeling changes. The holder must also assess the effects of any manufacturing change before distributing product made with it.1
What has to be reported when a batch of an approved drug fails its specification? The NDA applicant submits a field alert report to the responsible FDA district office within 3 working days of receipt of the information. The report covers bacteriological contamination, significant chemical, physical or other change or deterioration in the distributed product, and failure of one or more distributed batches to meet the specification established in the application. It may be made by telephone or other rapid means with prompt written followup.1
Can an applicant be excused from an electronic submission requirement? Under § 600.90 an applicant may ask FDA to waive any requirement applying to it under §§ 600.80 and 600.81, with supporting documentation. Temporary waivers of the electronic format requirements for safety reports and distribution reports are granted on a limited basis for good cause shown. FDA issues guidance on how to request such a waiver.2
Footnotes
-
21 CFR Part 314, Applications for FDA Approval to Market a New Drug. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22
-
21 CFR Part 600, Biological Products: General. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-600 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11
Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.